quartr
PEN: Q2 2026 revenue grew 14.9% year-over-year, with a $14.5B merger with Boston Scientific announced
Q2 2026 revenue rose 14.9% year-over-year to $390 million, with strong growth in both thrombectomy and embolization/access products, especially in the U.S. Net income declined due to higher taxes and operating expenses. The company announced a $14.5 billion merger with Boston Scientific, expected t…